Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Exudative and Vasogenic Chorioretinal Diseases
NCT00470977Phase 2Completed
- Sponsor
- Manhattan Eye, Ear and Throat Hospital
- Start
- May 2007
- Primary completion
- Dec 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in Coats disease, idiopathic juxtafoveal telangiectasia (IJT), retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy (PCV), pseudoxanthoma elasticum (PXE), sponsored by Manhattan Eye, Ear and Throat Hospital. Started May 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
Coats diseaseidiopathic juxtafoveal telangiectasia (IJT)retinal angiomatous proliferation (RAP)polypoidal choroidal vasculopathy (PCV)pseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on NCT00470977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470977.